GSK India to foray into haemato-oncology with BLENREP launch; adds Calpol 500 and Eltroxin line extensions in Q2 FY2027
GSK India says it will foray into haemato-oncology with the launch of BLENREP (belantamab mafodotin).
By ScoutQuest · · 1 min read
- Revenue, Q2 FY27
- up 21% YoY
- New product launch
- BLENREP (belantamab mafodotin), an anti-BCMA antibody-drug conjugate indicated for relapsed or refractory multiple myeloma
- Product line extensions
- Calpol 500 Suspension and Eltroxin 62.5 mcg and 150 mcg line extensions
- Release
- Results press release
- Period
- Q2 FY27
_Consolidated · Q2 FY27_
📊 Revenue, Q2 FY27: up 21% YoY
🔬 GlaxoSmithKline Pharmaceuticals Ltd says it will foray into haemato-oncology with the launch of BLENREP (belantamab mafodotin), an anti-BCMA antibody-drug conjugate indicated for relapsed or refractory multiple myeloma in adult patients who have received at least one prior therapy.
🔬 The company says its Oncology business, led by Jemperli (dostarlimab) and Zejula (niraparib), completed its first full year of commercialisation and saw accelerated momentum.
📌 The company achieved a Guinness World Records title for the "Largest Brochure Mosaic-Image" on World Heart Day (September 29), created at its Mumbai headquarters using pledge cards from more than 5,000 healthcare professionals.
📌 Managing Director Bhushan Akshikar says a dynamic geopolitical environment continues to drive inflationary pressures and supply chain risks for the business.
Also from GlaxoSmithKline Pharmaceuticals
Q2 results, new Ethics & Compliance Head and new Statutory Auditors approved by board
3 Nov 2026
Board approves Q2 results, new Ethics & Compliance Head and Walker Chandiok as statutory auditors
3 Nov 2026
GSK Pharmaceuticals schedules digital group investors/analysts meet on 4 November 2026
28 Oct 2026
More numbers
- Revenue, Q2 FY27INR 1180 crore
- Profit After Tax (PAT), Q2 FY27INR 335 crore
- Revenue growth, Q2 FY2721%
- PAT growth, Q2 FY2731%
- EBITDA growth, Q2 FY2720%
- Healthcare professionals in record mosaicmore than 5,000
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.